Format

Send to

Choose Destination
Pediatr Ann. 2017 Jan 1;46(1):e8-e12. doi: 10.3928/19382359-20161213-03.

Intravenous Immunoglobulin in the Treatment of Primary Immunodeficiency Diseases.

Abstract

Intravenous immunoglobulin (IVIG) has been used as antibody replacement therapy in primary immunodeficiency diseases (PIDDs) for more than 50 years. Its role as a therapeutic agent has expanded over the past couple of decades as its anti-inflammatory and immune-modulatory mechanisms of action have been elucidated. It is now used "off-label" to treat other autoimmune diseases. This article focuses on the role of IVIG in the treatment of PIDDs characterized by absent or deficient antibody production. Replacement doses are given on a monthly basis in these conditions as a prophylactic measure to prevent acute and serious bacterial infections. [Pediatr Ann. 2017;46(1):e8-e12.].

PMID:
28079912
DOI:
10.3928/19382359-20161213-03
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for SLACK Incorporated.
Loading ...
Support Center